Triple Hormonal Blockade (ADT3): A Patient’s Perspective
January 2019
in “
Oncogen
”
Studysummary This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age. Our plain-language summary of this paper — not a Tressless recommendation.
The document discussed the use of Triple Hormonal Blockade (ADT3) in managing prostate cancer, which involved a combination of a GnRH agonist or antagonist, an antiandrogen, and a 5Alpha Reductase inhibitor to effectively reduce testosterone and dihydrotestosterone (DHT) levels, thereby inhibiting cancer cell growth. It highlighted the importance of these medications in various treatment stages and emphasized the need for physicians to conduct necessary tests to rule out cardiac risks, especially in patients with pre-existing cardiovascular conditions, diabetes, or those over 70. The document also referenced a report suggesting that using the GnRH antagonist degarelix could potentially reduce cardiac events in patients with cardiovascular disease compared to GnRH agonists.
